Retinal ganglion cell survival Axonal regeneration a b s t r a c t
Introduction
It is well described that in adult mammals most of the retinal ganglion cells (RGCs) fail to regenerate their axons after optic nerve crush or transection and undergo apoptosis. This regeneration failure has been attributable both to the inhibitory environment of the central nervous system and the intrinsic inability of RGCs to regenerate (Schwab et al., 1993; Goldberg, 2004) . Because of that, many groups have been testing different approaches in order to promote RGC survival and axonal outgrowth following optic nerve injury. Among these approaches, there is induction of inflammation either by lens puncture or Zymosan injection (Fischer et al., 2000; Leon et al., 2000; Yin et al., 2003) and the stimulation of RGCs intrinsic program to regenerate through, for example, the deletion of the phosphatase and tensin (PTEN) (Park et al., 2008) and/or the deletion of the homolog suppressor of cytokine signaling 3 (SOCS3) (Smith et al., 2009; Sun et al., 2011) . The combination of PTEN deletion with Zymosan injection and elevation of intracellular cAMP leads to long distance regeneration and functional recovery (Kurimoto et al., 2010; de Lima et al., 2012) .
However, these different approaches are not easily translated to clinic. Regarding this, a developing strategy involves cell therapy with the transplantation of bone marrow derived cells or other cell types. Cell therapy has been used in different animal models of neurological diseases and lesions with interesting results (Giraldi-Guimaraes et al., 2009; Ribeiro-Resende et al., 2009; Johnson et al., 2010; Moraes et al., 2012; Suzuki et al., 2012; de Vasconcelos dos Santos et al., 2010; Vasconcelos-dos-Santos et al., 2012) and it is beginning to be used in clinical trials (Barbosa da Fonseca et al., 2009 Battistella et al., 2011; Friedrich et al., 2012; Rost et al., 2012) . Interestingly, data from clinical studies suggests that an intravitreal injection of autologous bone-marrow-derived cells into the vitreous cavity is technically feasible and safe (Jonas et al., 2008 , Siqueira et al., 2011 .
In the visual system, bone marrow mesenchymal cells have been transplanted intravitreally in two different models of glaucoma and showed neuroprotective results (Yu et al., 2006; Johnson et al., 2010) . It has also been shown that brainderived neurotrophic factor (BDNF)-secreting mesenchymal cells increases RGC survival in chronically hypertensive rat eyes (Harper et al., 2011) and that modified bone marrow mesenchymal cells increased neuroprotection after optic nerve transection (Levkovitch-Verbin et al., 2010) . Increased neuronal survival was also obtained after bone marrow mesenchymal cells transplantation in a model of lesion by ischemia/reperfusion ).
In previous work, our group demonstrated increase in RGC survival and axonal outgrowth 14 days after optic nerve crush and BMMC transplantation (Zaverucha-do-Valle et al., 2011) . We have also identified two proteins-Tax1-binding protein 1 and Synaptotagmin IV-that were up-regulated after optic nerve crush and cell therapy (Mesentier-Louro et al., 2012) . However, in most of these studies the effects were analyzed 14 days after treatment and it was important to investigate whether BMMC transplantation effects could still be present after a longer period of time. Therefore, in the present work, we analyzed neuroprotection and axonal regeneration 28 days after nerve injury and BMMC transplantation.
Results

BMMC transplantation increases axonal outgrowth 28 days after injury
To evaluate if the effect of BMMC transplantation on regeneration (Zaverucha-do-Valle et al., 2011) was sustained, we analyzed the axonal outgrowth 28 days after injury and cell therapy. For that, we used cholera toxin subunit B conjugated to Alexa-488 (CTB) as anterograde marker to visualize axons. In untreated animals ( Fig. 1(A) ), we observed a very small number of axons crossing the injury site (n). After BMMC transplantation, we noticed an increase in the number of axons distal to the lesion ( Fig. 1(B) ) when compared with the untreated group.
We quantified the number of CTB-labeled axons extending to 0.5, 1.0, 1.5 and 2 mm from the crush site using the formula described by Leon and co-workers (Leon et al., 2000) . The untreated animals had a median of 163.9 axons per nerve at 0.5 mm; 52.8 axons at 1 mm; 2.3 axons at 1.5 mm and 0 axons at 2 mm from the crush site (n ¼8). The animals that received BMMC transplantation had a median of 819.2 axons per nerve at 0.5 mm (n¼ 5); 454.9 axons at 1 mm (n¼ 5); 304.5 axons at 1.5 mm (n ¼4) and 15.8 axons at 2 mm (n¼ 3) from the crush site. BMMC transplantation generated a 5-fold significant increase (po0.01) in the number of CTB-labeled axons at 0.5 mm from the crush site, a 8.6-fold significant increase (po0.01) in the number of CTB-labeled axons at 1 mm from the crush site and a 129.8-fold significant increase (po0.05) in the number of CTB-labeled axons at 1.5 mm from the crush site. At the distance of 2 mm from the injury site, there was no statistically significant difference between the two conditions (p40.05). Fig. 1(C) shows the quantified data.
These results were confirmed by using GAP-43 staining. We quantified the number of GAP-43 þ axons located at 0.5, 1.0, 1.5 and 2 mm from the injury site and we estimated the number of axons per nerve using the formula described by (Leon et al., 2000) . The untreated animals had a median of 220.9 axons per nerve at 0.5 mm (n¼ 3); 46.7 axons at 1 mm (n¼ 8); 41 axons at 1.5 mm (n¼ 3) and 0 axons at 2 mm (n¼8) from the crush site. The BMMC-treated animals had a median of 583.5 axons per nerve at 0.5 mm (n¼ 4); 258.9 axons at 1 mm (n¼10); 65.6 axons at 1.5 mm (n¼ 5) and 21 axons at 2 mm (n¼ 10) from the crush site. We observed a significant increase in the number of GAP-43 þ axons located at 1 mm from the crush site after BMMC transplantation. Fig. 1(D) shows the quantified data.
2.2.
The BMMC transplantation effect on RGC survival is not sustained 28 days after injury
To evaluate if the effect of BMMC transplantation on neuroprotection (Zaverucha-do-Valle et al., 2011) was also sustained, we analyzed RGC survival 28 days after injury and cell therapy. For that, we used the retrograde tracer DiI or the antibody Tuj1. Fig. 2(A) illustrates DiI labeled RGCs and virtually intact axonal bundles in the contralateral, uninjured retinas. In contrast, twenty-eight days after optic nerve crush, the number of surviving RGCs is very small, both in the untreated and the treated conditions ( Fig. 2(B) and (C)). Fig. 2(G) shows the quantification of the data. Untreated animals (n¼ 8) showed a survival of 15.9571.78% RGCs and BMMC-treated animals (n¼9) had a survival of 13.4571.18% RGCs compared to contralateral uninjured retinas.
These results were confirmed by using another technique to label RGCs, the Tuj1 antibody. Using this technique, we can notice that virtually all RGCs are labeled in the uninjured retinas ( Fig. 2(D) ). After optic nerve crush, there is a great reduction in the number of surviving RGCs, both in untreated and treated conditions ( Fig. 2 (E) and (F)). Fig. 2(H) shows the quantification of the data. Untreated animals had 12.717 1.91% of Tuj1þRGCs and BMMC-treated animals had 11.587 2.19% of Tuj1þRGCs compared to contralateral uninjured retinas. However, we observed that, in BMMC-treated retinas, RGC cells stained with Tuj1 exhibit a typical morphology, brighter staining and more intact axons in several of the analyzed retinas (arrows and arrowheads in Fig. 2 (E) and (F)), suggesting that the treatment may have other beneficial effects that are not related to cell survival. þ axons located at 0.5, 1, 1.5 and 2 mm from the crush site 28 days after the injury. Graphs represent median and interquartile range. Scale bar: 125 μm.
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These results suggest that although we verified a difference on axonal outgrowth comparing treated to untreated animals 28 days after injury, the number of surviving RGCs is similar in both conditions. This suggests that there are probably different mechanisms related to axon regeneration and neuronal protection.
2.3.
Expression of trophic factors one day after optic nerve crush
In order to investigate possible mechanisms related to the observed effects, we analyzed mRNA levels of different trophic factors that have been previously associated to optic ) and (E) Twenty-eight days after optic nerve injury, there is a great reduction in the number of RGCs (arrowheads) and thinning of axon bundles (arrows). (C) and (F) In treated animals, the number of surviving RGCs is similar to untreated ones. However, cell morphology (arrowheads) and integrity of axon bundles (arrows) revealed by Tuj1 staining are qualitatively better preserved. (G) and (H) Quantification of RGC survival 28 days after the crush using DiI retrograde labeling (G) or Tuj1 labeling (H). (% of DiIþ or Tuj1þRGCs relative to normal). For DiI labeling, n¼ 8 (crushþsaline) and n¼ 9 (crushþBMMC). For Tuj1 labeling, n¼4 (crushþsaline) and n¼ 6 (crushþBMMC). Scale bar: 50 μm. Fig. 3 -mRNA levels of trophic factors after optic nerve crush and cell therapy. Quantification of FGF-2 (A), BDNF (B), Oncomodulin (C), CNTF (D), VEGF (E) and mRNA levels by real time RT-PCR 1 day after injury. We can note that 1 day after injury there is a significant increase in FGF-2 mRNA levels after cell therapy (po0.05). Values of the graphs represent the means 7 standard error of the mean. Values were normalized to the control group mean and GAPDH was used as loading control. nerve regeneration. We analyzed the mRNA levels of FGF-2 (Sapieha et al., 2003) , vascular endothelial growth factor (VEGF) (Kilic et al., 2006) ciliary neurotrophic factor (CNTF) (Weise et al., 2000; Muller et al., 2007; Muller et al., 2009 ), BDNF (Mansour-Robaey et al., 1994 Isenmann et al., 1998; Galindo-Romero et al., 2013) and oncomodulin (Yin et al., 2006 (Yin et al., , 2009 ) by real time PCR 1 day after optic nerve crush. We chose a time point when the BMMCs would still be present to select a factor to be further analyzed 28 days after the injury. Fig. 3 shows the quantified data. Values were normalized with mRNA levels in control retinas and GAPDH was used as loading control.
We can notice that there was a significant increase in FGF-2 mRNA levels ( Fig. 3(A) ) in BMMC-treated animals one day after injury compared with untreated animals. For the other analyzed factors, there were no statistically significant differences between treated and untreated animals.
2.4.
FGF-2 expression in the retina 28 days after optic nerve crush
As the FGF-2 was the only analyzed factor that was upregulated after cell therapy one day after injury, we analyzed the expression of this factor in the retina 28 days after the injury by imunohistochemistry. In previous work, our group showed that there is an increase in FGF-2 expression in the treated animals 14 days after the crush (Zaverucha-do-Valle et al., 2011) and we speculated that this increase could be related to the BMMC effects on RGC survival and axon outgrowth. After 28 days, we observed FGF-2 expression both in the inner nuclear layer and in the nerve fiber layer in both untreated (Fig. 4(A) ) and treated animals ( Fig. 4(B) ). We quantified the fluorescence intensity in the different retinal layers of untreated and BMMCtreated animals, and we observed there was no difference between the groups. This suggests that the increased expression of FGF-2 in BMMC-treated animals observed 14 days after injury was not sustained. Fig. 4 (C) shows the quantified data.
Transplanted cells do not remain in the eye for a long period of time
To investigate the fate of transplanted cells, we used different techniques. For short-term tracking, we either labeled the BMMCs with a radioisotope ( 99m Tc) and analyzed by scintigraphy or we labeled them with a fluorescent dye (CellTrace) and analyzed by flow cytometry. Fig. 5 shows that 1 h after optic nerve crush and cell transplantation 99m Tc activity was not found in any other organ of the body and was restricted to the eye, suggesting that BMMCs do not enter the bloodstream shortly after transplantation. This can be seen in the sagittal ( Fig Tc activity combined with a CT image. Because of the short half-life of the 99m Tc, its activity could not be detected for a longer period of time.
Animals that received CellTrace-labeled BMMCs were analyzed one and three days after optic nerve crush and cell transplantation by flow cytometry. In Fig. 5 (F) we can notice that prior to transplantation, most of the BMMCs were labeled with CellTrace, demonstrating the efficiency of labeling. In Fig. 5 (G) we can see that there is no unspecific staining in uninjured eyes and in Fig. 5 (H) and (I) there is a huge decrease in the number of transplanted cells in the eye of the host from one ( Fig. 5(H) ) to three days ( Fig. 5(I) ) after the injection.
For a long-term tracking, we labeled the BMMCs with SPION and analyzed them by in vivo MRI 1, 5 and 14 days after optic nerve crush and cell transplantation. In Fig. 6 (A)-(D), we can see the dextran-coating (in green) of the dissociated BMMC labeled with SPION before transplantation. Nuclei are stained with TO-PRO-3 (in green). We can note that although the efficiency of SPION incorporation seems high, each cell can only incorporate a few particles. In Fig. 6 (E), we can see that one day after optic nerve crush and BMMC injection, there is a high number of dextran-labeled cells (in red) in the vitreous body. Nuclei are stained with TO-PRO-3 (in green).
Fig. 6(F) shows MRI images 1, 5 and 14 days after unilateral optic nerve crush (left eye) and injection of SPION-labeled BMMCs. The signal of the iron in the transplanted cells is more evident one day after injection and it appears as a hypointense, dark spot close to the lens (arrows). This can be seen in the coronal, horizontal and sagittal planes. Five days after transplantation, we can note a decrease in the hypointense signal, which is more evident in the coronal plane. Finally, 14 days after the injection, the hypointense signal derived from the transplanted cells is almost absent, suggesting that there is a fast decrease in the number of BMMC cells in the eye.
2.6.
A second BMMC injection does not prolong RGC survival 28 days after injury As the number of cells that remain in the eye 14 days after injection is very small, we speculated that the transitory effect of BMMC transplantation on RGC survival could be related to the short persistence of these cells in the eye. Therefore, we performed a second injection of BMMCs 7 days after the first one to verify if a new exposure to the transplanted cells could prolong RGC survival. Untreated animals received two injections of saline at the same time points. Animals were analyzed 28 days after optic nerve crush.
Twenty-eight days after injury, we can notice that there is no statistically significant difference between the animals that received two injections of BMMCs (Fig. 7(B) ) when compared to animals that received two injections of saline ( Fig. 7(A) ). Animals that received two saline injections (n ¼8) had a mean of 12.7671.83% RGCs and animals that received two BMMC injections (n¼ 14) had a mean of 16.0171.56% RGCs compared to contralateral uninjured retinas. Fig. 7(C) shows the quantification of the data. This demonstrates that a second injection of BMMC does not prolong RGC survival.
Besides quantifying neuronal survival on these animals, we also analyzed the axonal outgrowth by GAP-43 staining. As previously done, we quantified the number of GAP-43 þ b r a i n r e s e a r c h 1 5 8 7 ( 2 0 1 4 ) 5 4 -6 8 axons located at 0.5, 1.0, 1.5 and 2 mm from the injury site. Animals that received two injections of saline had a median of 264.1 axons per nerve at 0.5mm (n ¼6); 176.9 axons at 1 mm (n ¼ 6); 27.2 axons at 1.5 mm (n¼ 6) and 0 axons at 2 mm (n¼ 6) from the crush site. Animals that received two injections of BMMC had a median of 967.7 axons per nerve at 0.5 mm (n¼ 8); 620.3 axons at 1 mm (n ¼10); 124.9 axons at 1.5 mm (n¼ 10) and 20.3 axons at 2 mm (n¼ 10) from the crush site.
The two injections of BMMC generated a 3.6-fold significant increase (po0.05) in the number of GAP-43 þ axons at 0.5 mm from the crush site, a 3.5-fold significant increase (po0.05) in the number of GAP-43 þ axons at 1 mm from the crush site and a 4.6-fold significant increase (po0.05) in the number of GAP-43 þ axons at 1.5 mm from the crush site when compared to two saline injections. At the distance of 2 mm from the injury site, there was no statistically significant difference between the two conditions (p40.05). Fig. 7(D) shows the quantified data. Interestingly, comparing the median of the number of axons located at 1 mm from the crush site after one (454.9 axons) or two BMMC injections (620.3 axons), we can notice that after two injections, there is a higher number of axons at this distance. The difference is statistically significant (po0.05), demonstrating that a second dose of BMMC improves the effect of a single dose on axonal regeneration ( Supplementary Fig. 1A) .
However, comparing the median of the number of axons located at 1mm from the crush site after one (46.73 axons) or two saline injections (176.9 axons), there is also a statistically significant difference (po0.05) ( Supplementary Fig. 1(B) ), suggesting a possible role of inflammation in these results.
To verify that a second injection of BMMC increased the persistence of the cells in the eye, we labeled the BMMCs Tc prior to transplantation. Whole-body and localized scintigraphies were performed in these animals for qualitative biodistribution in a dedicated small animal SPECT/CT camera equipped with a high-resolution collimator and diagnostic CT 1 h after injection. In the sagittal (A), coronal (B) and horizontal (C) planes, we can see that the 
again with SPION and analyzed the animals that received two BMMC injections by in vivo MRI 1, 8 and 14 days after optic nerve crush. Fig. 8 shows MRI images of coronal, horizontal and sagittal planes 1, 8 and 14 days after unilateral optic nerve crush (left eye). Labeled cells were injected at the same day of optic nerve crush and 7 days after the first injection. Similar to what we observed after a single BMMC injection, the signal of the transplanted cells is more evident one day after injection and it decreases in the subsequent days. By comparing Fig. 8 to Fig. 6(F) , we can notice that two weeks after optic nerve crush, the iron signal from the SPION BMMC is very similar after one (Fig. 6(F) ) or two injections (Fig. 8) , suggesting that a second dose of BMMC does not increase persistence of the transplanted cells in the eye.
Discussion
In previous work, our group demonstrated that BMMC transplantation increases RGC survival and axonal outgrowth 14 days after optic nerve crush (Zaverucha-do-Valle et al., 2011).
In the present work, we investigated if this effect was sustained for a longer period of time and we analyzed the effect of a second injection of BMMC. Although other studies have used bone marrow-derived mesenchymal cells for cell therapy in the visual system (Johnson et al., 2010; Levkovitch-Verbin et al., 2010) , we used BMMCs because these cells can be easily transplanted from donor to recipient without cell culture, making translation to clinic simpler. Another potential advantage of using these cells is that they are a heterogeneous population and cell types other than the mesenchymal cells may also play a role in the treatment.
We have previously characterized that the BMMC fraction we inject has around 24% of lymphocytes, 55% of granulocytes and 16% of monocytes (Gubert et al., 2013 ) and these cells can release cytokines and/or growth factors in response to stimulus. Our group has demonstrated, for example, increased in BDNF and FGF-2 levels after global ischemia and sciatic nerve injury respectively in animals that received BMMC transplantation (Ribeiro de Resende et al., 2012; Gubert et al., 2013) . It is also possible that paracrine interactions between mesenchymal cells and other bone marrow-derived cells might be beneficial. b r a i n r e s e a r c h 1 5 8 7 ( 2 0 1 4 ) 5 4 -6 8
We analyzed both RGC survival and axonal outgrowth 28 days after optic nerve crush. We observed that BMMC-treated animals had a higher number of axons located at 0.5, 1 and 1.5 mm from the crush site when compared to untreated animals at this time point. If we compare the median of the number of axons located at 0.5, 1.0 and 1.5 mm from the crush site 14 days (Zaverucha-do-Valle et al., 2011) and 28 days after optic nerve crush and cell therapy, we can notice that the median is always higher at the longest time point (423.8 axons versus 819.2 axons at 0.5 mm; 174.6 axons versus 454.9 at 1 mm; 77.1 axons versus 304.5 axons at 1.5 mm). This comparison suggests that the axons continue to grow from 14 to 28 days after injury.
However, 28 days after optic nerve crush, the number of RGCs that remained alive was similar in treated and untreated animals, suggesting that the BMMC effect on RGC survival was transient. This is not the first report of a therapy that promotes axonal outgrowth without promoting retinal ganglion cell survival. Yin and co-workers, for example, showed that oncomodulin released from microspheres promotes regeneration in the optic nerve, but the protein does not improve neuronal survival in vitro (Yin et al., 2006) .
It has also been shown that FGF-2 up-regulation in adult RGCs by gene delivery has a transient effect on RGC survival following optic nerve crush (Sapieha et al., 2003) . Fourteen days after the injury, the authors demonstrated increased axonal outgrowth following FGF-2 up-regulation in spite of low RGC survival (Sapieha et al., 2003) . There are different reports showing that promoting RGC survival is not enough to improve axonal regeneration (Lodovichi et al., 2001; Inoue et al., 2002) , suggesting that neuronal survival and axonal outgrowth follow different pathways.
In order to investigate possible factors that could be responsible for the BMMC effect, we analyzed the mRNA levels of FGF-2, VEGF, CNTF, BDNF and oncomodulin and we demonstrated an increase in FGF-2 mRNA levels 1 day after optic nerve crush. This increase is still evident 14 days after optic nerve crush (Zaverucha-do-Valle et al., 2011), but after 28 days, the FGF-2 levels are very similar in treated and untreated animals. Therefore, the effects of BMMC transplantation on RGC survival could be related to FGF-2 release and, consequently, would be transitory.
Analyzing the permanence of transplanted cells in the eye by MRI, we demonstrated that the number of BMMCs in the eye is very low 14 days after transplantation. Therefore, the transitory effects on neuroprotection could be associated to the short persistence of the transplanted cells in the eye that is probably due to their low integration into the retina. This low integration has been reported in different models (Yu et al., 2006; Johnson et al., 2010) .
Short-term effects on RGC survival have also been shown after cell therapy in other models. Wu and co-workers, for example, have shown increased neuronal survival 7 days after optic nerve transection and injection of olfactory ensheathing cells into the ocular stumps, but these effects were not sustained after 14 days (Wu et al., 2010) .
In an attempt to prolong the effects on RGC survival, we performed a second injection of BMMC 7 days after the first one. We verified that even with the second dose, there was still no statistically significant difference on RGC survival between treated and untreated animals. That was not the first report showing that multiple cell injections did not improve the therapy outcome. Omori and co-workers, for example, injected a single dose or multiple doses of human mesenchymal stem cells systemically after cerebral artery occlusion in rats and verified that the single dose had the greatest therapeutic effect when compared to the multiple injections (Omori et al., 2008) . Similarly, Zhang et al. (2011) showed that multiple injections (either two or three injections) of bone marrow cells did not decrease the infarct size in a model of myocardial infarction .
A possible explanation for the lack of effect of the second injection on RGC survival is that the window of treatment is very narrow since the RGCs activate apoptotic pathways and start to die within the first days after optic nerve injury. Therapy should act on early time points to avoid the entrance of cells in the degenerative process. Once the cells are committed to die, it might be too late to promote survival. Our results suggest that BMMC transplantation does not prevent cell death but, instead, delays it, explaining why RGCs are more preserved 14 days after the lesion but not after 28 days. For that reason, giving an additional injection of BMMCs 7 days after the first treatment may be too late to improve survival.
Interestingly, although the second BMMC injection did not improve RGC survival, we can notice an effect on axonal outgrowth. By comparing the median of the number of axons located at 1mm from the crush site after one or two BMMC injections, there is a higher number of axons after two injections. This demonstrates that a second dose of BMMC improves the effect of a single dose on axonal regeneration. However, as mentioned previously, two injections of saline also generates a higher number of axons at 1 mm from the crush site than one injection of saline. This suggest that although we excluded from the analysis animals that had lens injury, the additional injection of vehicle by itself improved axonal outgrowth, possibly by inducing a low inflammatory process. Therefore, a single injection of BMMCs followed by a second injection of vehicle may be a good option to improve axonal regeneration. However, it is important to mention that performing a second injection increases the chances of injuring the lens and/or damaging the retina and the risk should be considered for clinical purposes.
In conclusion, cell therapy using bone marrow mononuclear cells improves axonal outgrowth and this effect is sustained at least up to 28 days after optic nerve crush. In previous work, we demonstrated that a few axons were able to reach the brain 60 days after treatment, suggesting that the BMMC transplantation on axonal outgrowth is prolonged (Zaverucha-do-Valle et al., 2011) . However, at this time point, RGC survival is similar in untreated and treated animals, suggesting that neuronal survival and axonal regeneration follow different pathways. A second dose of BMMC could not rescue the retinal ganglion cells. Therefore, in order to achieve long-term effects on neuroprotection, it would be important to find other types of cells that could persist in the tissue for a longer period of time.
It has been demonstrated that bone marrow-derived mesenchymal cells can survive in the brain for at least 60 days (Moraes et al., 2012) and in the vitreous cavity for at least 5 weeks (Johnson et al., 2010) . Both BMMC and mesenchymal cells express growth factors ( (Yu et al., 2006; Li et al., 2009; Zaverucha-do-Valle et al., 2011; Ribeiro de Resende et al., 2012; Johnson et al., 2014) and both populations have been used in different models with similar results ((de Vasconcelos Dos Santos et al., 2010; Lindoso et al., 2011; Abreu et al., 2013) . Therefore, it would be interesting to analyze if mesenchymal cells could prolong RGC survival.
Alternatively, it would also be interesting to combine cell therapy using BMMC with other strategies to increase RGC survival, such as lens injury (Fischer et al., 2000; Leon et al., 2000) zymosan injection (Yin et al., 2003) , bcl-2 overexpression (Chierzi et al., 1999) or PTEN and SOCS-3 deletion (Park et al., 2008; Smith et al., 2009; Sun et al., 2011) .
4.
Experimental procedure
Bone marrow mononuclear cell extraction
All the experiments were performed according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the protocols were approved by the Committee for the Use of Experimental Animals of our Institution. Bone marrow mononuclear cell extraction was performed as previously described (Zaverucha-do-Valle et al., 2011; Vasconcelosdos-Santos et al., 2012) . Briefly, the bone marrow was extruded from their tibias and femurs of syngeneic donor Lister-hooded adult rats. The isolated bone marrow was dissociated in DMEM-F12 (GIBCO BRL, Grand Island, NY, USA) and separated by density gradient on Histopaque 1083 (Sigma, St. Louis, MO, USA). The mononuclear fraction was then collected, washed three times with phosphate-buffered saline (PBS) and resuspended in saline (0.9% NaCl).
Optic nerve crush and intraocular injections
Optic nerve was crushed in a procedure similar to previously described (Berry et al., 1996) . Briefly, Lister-hood adult rats (3-5 months old) were anesthetized with ketamine (50 mg/kg) and xylazine (5 mg/kg) and an incision was made in the skin under a stereoscopic microscope. The left optic nerve was exposed, the epineurium was opened and the optic nerve was crushed 1 mm behind the eye with angled tweezers for 15 s avoiding injury to the ophthalmic artery. Immediately after the optic nerve crush, we injected 5 μl of saline or 5 Â 10 6
BMMCs ressuspended in 5 μl of saline using a 5-μl Hamilton syringe avoiding injury to the lens. Animals that received two injections of saline or BMMCs had the first injection immediately after the crush and the second injection after 7 days. The second injection was always performed in the side of the eye opposite to the first injection to avoid further damage. Lesion was always performed in one eye and the contralateral eye was used as control. Animals were kept in a warm cage for anesthesia recovery and received food and water ad libitum after being transferred to animal facility.
BMMC labeling with CellTrace and flow cytometry
For flow cytometry analyses, BMMCs were labeled with the fluorescent dye CellTrace™ FarRed DDAO-SE (2.5 mg/mL) (Invitrogen) for 40 min at 37 1C and 5%/95% CO 2 /air. After incubation, cells were washed three times in PBS and prepared for administration as described previously. One and 3 days after optic nerve crush and BMMC transplantation, animals were euthanized. The vitreous body and the retina were isolated and retina was dissociated using a papain digestion protocol. Briefly, retinas were incubated in papain solution (Worthington Biochemical Corporation, Lakewood, NJ, USA) for 30 min at 37 1C and 5%/95% CO 2 /air. Cells were then washed there times in DMEM-F12 (GIBCO BRL, Grand Island, NY, USA) and resuspended in PBS for flow cytometry analyses. Cells were incubated with DAPI to verify cell viability and were analyzed in a BD FACS Aria II flow cytometer (BD Biosciences). Acquired data were analyzed by FlowJo v.7.6.4 software (FlowJo, USA).
4.4.
BMMC labeling with 99m Technetium ( 99m
Tc) and in vivo scintigraphy
For short-term track of the transplanted cells, BMMCs were labeled with 99m Tc following protocols described previously Quintanilha et al., 2008; Vasconcelosdos-Santos et al., 2012) . Briefly, 500 μL of sterile SnCl 2 solution was added to the cell suspension in 0.9% NaCl and the mixture was incubated at room temperature for 10 min. Then, 5 mCi of 99m Tc was added and the incubation continued for another 10 min. After centrifugation (500 Â g for 5 min), the supernatant was removed and the cells were resuspended in 0.9% NaCl. Viability of the labeled cells was assessed by the trypan blue exclusion test, and was estimated to be greater than 93% in all cases. Labeling efficiency (%) was calculated by the activity in the pellet divided by the sum of the radioactivity in the pellet plus supernatant, and was estimated to be greater than 90% in all cases. A total of 5x 10 6 99m Tc-BMMCs were injected direct into the vitreous body of adult rats as previously described. Wholebody and localized scintigraphies were performed in these animals 1 h after injection for qualitative biodistribution in a dedicated small animal SPECT/CT camera (Triumph, Gammamedica ideas, Canada) equipped with a high-resolution collimator and diagnostic CT.
BMMC labeling with SPION and in vivo magnetic resonance imaging (MRI)
For long-term track of the transplanted cells, BMMCs were labeled with superparamagnetic iron oxide (SPION) particles (FeraTrack Contrast Particles, Milteny Biotec, Bergisch Gladbach, Germany) . We used the protocol described by the manufacturer and cells were incubated with the particles for 3 h, at 37 1C and 5%/95% CO 2 /air. After this period of time, cells were washed three times with PBS and were resuspended in saline for further injection.
BMMCs labeled with SPION were tracked in vivo by MRI scanning 1, 5, 9, 14 or 16 days after optic nerve crush and cell transplantation. For MRI, animals were anesthetized by intraperitoneal injection of ketamine (50 mg/Kg) and xylazine (15 mg/Kg) and positioned in the MRI coil. Images were acquired in a 7-T magnetic resonance scanner (7T/210 horizontal Varian scanner, Agilent Technologies, Palo Alto, CA, USA), using fast spin echo (FSE) proton density (PD) sequences (matrix: 192x192, slice thickness: 0.5 mm; 15 continuous slices) in the axial (TR/TE: 1500/11 ms; field of view: 30 Â 30 cm), coronal (TR/TE: 2100/11 ms; field of view: 30 Â 30.5 cm) and sagittal (TR/TE: 1500/11 ms; field of view: 30 Â 30.5 cm) planes. Data processing was performed using MRIcron.
Immunohistochemistry
Twenty-eight days after optic nerve crush, animals were euthanized and perfused with saline followed by 4% paraformaldehyde and 4% paraformaldehyde with 10% sucrose. Eyes were then removed with the optic nerve attached. For retinal ganglion cell survival analysis, retinas were dissected, flat mounted and washed 3 times with 0.1% Triton X-100 in PBS. Flat-mounted retinas were then incubated in 5% normal goat serum (Sigma) in PBS at room temperature for 1 h and in Tuj1 antibody (1:500 in 0.1% Triton X-100 in PBS, Covance Inc., USA) at room temperature for 3 h followed by incubation at 4 1C overnight. The retinas were washed in PBS and then incubated with Cy3-conjugated goat anti-mouse IgG (1:1000, Jackson ImmunoResearch Lab. Inc., West Grove, PA, USA) for 2 h at room temperature. After washing (three times in PBS), retinas were mounted with VectaShield (Vector, Burlingame, CA, USA) onto glass slides and photographed on a Zeiss Axiovert 200M microscope equipped with an Apotome slide (Zeiss). To quantify RGC survival, we took 10 pictures of regions radially distributed at 1 mm from the optic disc, using a 40Â 0.75 NA objective. Counts were made by a blind observer. The statistical analysis was done using GraphPad Prism 5.02 (1992 -2004 , using an unpaired two-tailed t-test. For axonal outgrowth and basic fibroblast growth factor (FGF-2) expression analysis, nerves and eyes were embedded in optimal cutting temperature (OCT) compound (Tissue-Tek, Sakura, Japan) and cut longitudinally on a cryostat (Leica CM 1850, Microsystems Nussloch GmbH, Germany) at 14-20 μm thickness. Sections were collected on gelatin-coated slides. For immunohistochemistry analysis, sections were washed 3 times in PBS, incubated in 5% normal goat serum (Sigma) in PBS for 30 min at room temperature and incubated with primary antibodies overnight at 4 1C. Sections were then washed 3 times and incubated with the appropriate secondary antibodies for 2 h at room temperature. Nerves were stained with anti-growth-associated protein 43 (GAP-43) antibody (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by Cy3-conjugated goat anti-rabbit IgG (1:1000, Jackson ImmunoResearch Lab. Inc., West Grove, PA, USA) or Alexa 488-conjugated goat anti-rabbit IgG (1:200; Invitrogen Inc., Carlsbad, CA, USA). Retinas were stained with anti-FGF-2 antibody (1:100, EMD Millipore, Germany) followed by Cy3-conjugated goat anti-mouse IgG (1:1000, Jackson ImmunoResearch Lab. Inc., West Grove, PA, USA). In some cases the tissues were incubated with Sytox Green (500 nM; Invitrogen), bisbenzimide (0.01% in PBS, Sigma) or TO-PRO s -3 (1:1000, Invitrogen Inc) for nuclei counterstaining. After washing (three times in PBS), the slides were mounted with VectaShield (Vector Laboratories) and analyzed by confocal microscopy (Zeiss, LSM 510 META).
To visualize the SPIONs in the transplanted cells, we used an antibody against their dextran-coating. For that, both retinas of transplanted animals and dissociated cells plated on glass coverslips were washed 3 times with 0.1% Triton X-100 in PBS and incubated in 5% normal goat serum (Sigma) in PBS for 30 min at room temperature. The primary antibody (anti-dextran, 1:1000, StemCell Technologies, Vancouver, BC, Canada) was incubated overnight at 4 1C. After that, the cells or the tissue were washed with 0.1% Triton X-100 in PBS and incubated with the secondary antibody (Alexa488-antimouse, 1:1000, Invitrogen Inc) and TO-PRO s -3 to label nuclei (1:1000, Invitrogen Inc) for 2 h at room temperature. After washing, the slides were mounted with VectaShield (Vector Laboratories) and analyzed by confocal microscopy (Zeiss, LSM 510 META).
4.7.
Fluorescence intensity quantification
Twenty-eight days after optic nerve crush, retinas from untreated and BMMC-treated animals were labeled with anti-FGF-2 antibody and nuclei were counterstained with TO-PRO s -3 as described above. For fluorescence intensity quantification, Z stack images from the central and peripheral retinas were acquired using a confocal microscope (Zeiss LSM 510 Meta). We analyzed two images from each slice and three slices per animal. All the immunostaining reactions were performed simultaneously. Individual slices of each stack were analyzed using Image J software (NIH). Fluorescence intensity was measured separately in the nerve fiber layer (NFL) and ganglion cell layer (GCL), in the inner plexiform layer (IPL) and in the inner nuclear layer (INL), outer plexiform layer (OPL) and outer nuclear layer (ONL). We quantified only the FGF-2 labeling signal and the nuclei stained was used for identification of retinal layer. The average mean gray value per stack of BMMC-treated and untreated animals were acquired and used for statistical analysis. Quantifications were performed by a blind observer.
Retrograde labeling of retinal ganglion cells
In a different set of animals, retinal ganglion cell survival was quantified by retrograde labeling using the lipophilic tracer DiI (1,1 0 -dioctadecyl-3,3,3,3 0 -tetramethylindocar-bocyanine perchlorate, Invitrogen) (n¼ 16). DiI labeling was performed as previously described (Zaverucha-do-Valle et al., 2011) . Briefly, 4 μl of DiI (2.5% in dimethylformamide, Sigma) was delivered stereotaxically (6.3 mm posterior from Bregma; 1.2 mm lateral and 3.5 mm ventral) bilaterally into the superior colliculi 7 days before the optic nerve crush. For quantification of RGC survival, 28 days after optic nerve crush, animals were euthanized and the retinas were dissected without fixation, flat mounted, and fixed onto gelatinized glass slides with 4% paraformaldehyde for 15 min at room temperature. Retinas were then washed three times with PBS, covered with coverslips and photographed on a Zeiss Axiovert 200M microscope equipped with structured illumination microscopy (Apotome) and a MRm digital camera (Zeiss).
Ganglion cell axon labeling and quantification of axon outgrowth
For retinal ganglion cell axon labeling, we injected 4 μl of Cholera Toxin B subunit conjugated to Alexa488 (CTB) (Invitrogen, 0.2% diluted in PBS with 1% DMSO) into the vitreous body 26 days after optic nerve crush. Two days after injection, animals were perfused, optic nerves were dissected and histological preparation was similar to what was described above.
For quantification of axon outgrowth, we counted the number of GAP-43 þ axons or CTB-labeled axons located at 0.5, 1, 1.5 and 2 mm from the injury site. The total number of axons per nerve was calculated by using the formula described by Leon and co-workers (Leon et al., 2000) . Statistical analysis was done using GraphPad Prism 5.02 (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) GraphPad Software, Inc.) using a nonparametric unpaired one-tailed Mann-Whitney test. (Livak and Schmittgen, 2001 ).
Real Time quantitative PCR
